Developing vaccines to protect against Ebola and related viruses
Advanced Development of Vaccines for Filoviruses
This study is working on a new vaccine that could help protect people from serious viruses like Ebola, Marburg, and Lassa Fever, making it easier to store and transport so it can be used to keep everyone safe in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auro Vaccines LLC NIH-funded |
| Lab location | 1 site (East Windsor, United States) |
| Project ID | NIH-10610295 on NIH RePORTER |
What this research studies
This research focuses on creating a multivalent vaccine that aims to protect against several dangerous viruses, including Ebola, Marburg, and Lassa Fever. The approach involves formulating a stable vaccine that can be lyophilized, which means it can be freeze-dried for easier storage and transport. The project will also support the manufacturing of this vaccine under strict quality standards and prepare it for clinical evaluation, which is a crucial step before it can be made available to the public. Patients may eventually benefit from a vaccine that provides broader protection against these serious viral infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of exposure to Ebola, Marburg, or Lassa Fever, including healthcare workers and residents in endemic regions.
Not a fit: Patients who are not at risk of exposure to these viruses or who have already been vaccinated against them may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that protects against multiple deadly viruses, potentially saving lives and preventing outbreaks.
How similar studies have performed: Other research has shown promise in developing vaccines for filoviruses, indicating that this approach has potential based on previous successes.
Where this research is happening
East Windsor, United States
- Auro Vaccines LLC — East Windsor, United States (Active)
Researchers
- Principal investigator: Eldridge, John — Auro Vaccines LLC
- Study coordinator: Eldridge, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.